Gyrolab Spin Blog: hcp

Apr 6, 2020 8:18:44 PM

How to think about HCP impurity testing

Getting a meaningful result

How to think about HCP impurity testing

Many good points were raised when it comes to impurity testing at the latest Gyrolab User Seminar, held in Milan in June. This included a roundtable discussion on a subject that has been a stumbling block for many – how to measure Host Cell Protein (HCP) levels in a meaningful way.

Read More

Topics: HCP, Immunogenicity, Impurity testing

Jun 11, 2019 2:37:58 PM

Next generation antibody therapeutics move into prokaryotes

Smaller, simpler biotherapeutics pave the way for new production methods


Exploiting the advantages of E. coliMammalian expression systems have driven the rise of biotherapeutics. Their ability to introduce proper protein folding, post-translational modifications, and product assembly means that they are currently used to produce almost all therapeutic antibodies to ensure correct structure and minimize the risk of immunogenicity. But the advent of smaller, simpler biotherapeutics means that prokaryote expression systems such Escherichia coli (E. coli) are playing a new role in antibody therapy. These bacteria can deliver high expression levels, with simpler bioprocessing at a lower cost together with an extensive molecular toolbox based on well-characterized genetics. This development is increasing the need for sensitive methods to monitor bioprocess development and manufacturing based on E. coli-based expression systems, including the sensitive analysis of host cell proteins. 

Read More

Topics: HCP, Impurity testing, Gyrolab system, Host Cell Proteins

Oct 27, 2015 9:14:00 AM

High throughput screening in biologics process development with a minimum of material

Matching scale-down high throughput screening with efficient analytical methods makes the most of precious material

Combining high throughput and small-scale purification methods is a key strategy in bioprocess development. John Welsh and his colleagues at Merck & Co. Inc, USA could develop three orthogonal purification steps using less than 200 mg of a domain antibody fragment, orders of magnitude less than what would typically be required for process development. 


Read More

Topics: Bioprocess, HCP